The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage ...
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule ...
LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results